Optiscan Improving Cancer Outcomes with Digital Pathology & Precision Surgery, page-6

Cervical Cancer

My last post failed to properly distinguish detection and treatment of Cervical Canceras a future offshoot from InVivage. Cervical Cancer is the fourth most common cancer in females. It is most commonly diagnosed in females between ages 35 and 44 years. Symptoms include vaginal bleeding after sex or after menopause, bleeding between periods or periods that are heavier or longer than normal, discharge with a strong odour or discharge that contains blood, and or pelvic pain. The current detection process involves a pap test where the doctor scrapes and brushes cells from the cervix. However, a pap test is not definitive and more testing may be required with further samples having to be sent to the lab. Clearly, Optiscan’s digital biopsy is a more superior option for both detection and treatment (surgical or otherwise).

P.S.

For completeness, the current tests for women with symptoms are:

· Colposcopy

· Colposcopic biopsy

· Endocervical curettage (endocervical scraping)

· Cone biopsy

For those with cervical cancer in ascertaining the scope of the cancer the patient may be subjected to Computed tomography, Magnetic resonance imaging, Positron emission tomography, and or Intravenous urography.

Treatments amongst other things can involve a hysterectomy.